Scientists from the Institute of Cancer Research (ICR) have found a new method for predicting bowel cancer risk in ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030.

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

Rise in prevalence of ulcerative colitis and Crohn's disease, growing awareness of the disease across the world, drives the growth of the market David Correa Allied Market Research + 1 800-792-5285 ...

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...

The town of Northport is nestled on the banks of the Upper Columbia River, just a few miles south of the Canadian border. And for many of ...

Eight ways to reduce your risk of bowel cancer - Around half of all bowel cancers could be prevented by having a healthier lifestyle ...

Scientists from the Institute of Cancer Research (ICR), London, UK, have developed an algorithm that can predict whether ...

An international study led by the University of Oulu and Oulu University Hospital has identified six genetic regions ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

AbbVie’s ABBV 2024 revenue grew 4.6% on a constant currency basis, with 2025 guidance of 5.7% growth and new 2027 guidance for combined sales of immunology drug Skyrizi and Rinvoq of $31 billion (up ...